Collectively, above data suggested that DVL3 enhanced EMT and CSLCs characteristic via Wnt/β-catenin/c-Myc/SOX2 axis, which provided a new strategy for successful CRC treatment. This evidence concerns the gene MYC and colorectal carcinoma.